PGNY Stock Cash Flow Statements

Progyny Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Progyny Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31

operating activities
net income	17,112,000	15,059,000	10,532,000	10,421,000	16,485,000	16,898,000	13,470,000	15,898,000	14,991,000	17,678,000	3,408,000	13,211,000	8,768,000	4,971,000	15,080,000	16,796,000	18,727,000	15,166,000	38,859,000	5,355,000	-1,812,000	4,057,000	-4,400,000
adjustments to reconcile net income to net cash from operating activities:
deferred tax expense	12,000	11,000		4,829,000	2,645,000	2,877,000	-2,117,000	5,038,000										-3,370,000	-38,087,000	0	0	116,000	-77,000
non-cash interest income					113,000	-190,000	-92,000
depreciation and amortization	1,205,000	1,108,000	868,000	837,000	754,000	716,000	634,000	579,000	527,000	541,000	446,000	405,000	386,000	364,000	316,000	267,000	296,000	422,000	464,000	462,000	460,000	520,000	539,000
loss on disposal of property and equipment	0	79,000																					0
stock-based compensation expense	32,383,000	32,512,000	30,859,000	33,183,000	33,036,000	31,052,000	28,799,000	31,251,000	31,753,000	30,808,000	29,297,000	23,297,000	23,654,000	24,500,000	15,008,000	7,147,000	6,517,000	5,034,000	4,160,000	3,071,000	3,541,000	2,049,000	1,852,000
bad debt expense	5,358,000	5,659,000	3,662,000	3,162,000	4,800,000	4,772,000	4,872,000	5,268,000	4,550,000	5,244,000	4,109,000	3,588,000	3,816,000	2,281,000	2,562,000	2,416,000	2,287,000	2,518,000	1,853,000	1,240,000	1,212,000	1,257,000	274,000
net accretion of discounts on marketable securities	-1,079,000	1,106,000	1,644,000
foreign currency exchange rate loss						35,000	-20,000
changes in operating assets and liabilities:
accounts receivable	22,566,000	-69,732,000	41,705,000	9,917,000	-1,378,000	-60,118,000	22,023,000	-9,075,000	43,736,000	-78,422,000	13,859,000	-31,758,000	-35,560,000	-65,845,000	-1,938,000	3,170,000	-26,388,000	-43,520,000	-384,000	-14,552,000	-346,000	-20,054,000	-2,998,000
prepaid expenses and other current assets	-5,563,000	-2,383,000	20,414,000	-3,675,000	-13,890,000	15,169,000	-20,407,000	6,666,000	-7,733,000	-1,456,000	-1,658,000	1,294,000	1,085,000	-664,000	261,000
accounts payable	-4,411,000	49,618,000	-35,340,000	-21,324,000	21,606,000	4,790,000	-6,649,000	2,031,000	-15,592,000	36,445,000	4,982,000	11,632,000	7,904,000	23,171,000	6,166,000	583,000	-2,706,000	13,797,000	1,289,000	10,886,000	-7,526,000	20,359,000	-3,323,000
accrued expenses and other current liabilities	-11,657,000	17,509,000	-3,208,000	4,272,000	-4,135,000	12,995,000	-1,383,000	-2,085,000	2,078,000	11,751,000	-3,183,000	739,000	9,102,000	6,489,000	-10,905,000	3,552,000	124,000	9,413,000	2,381,000	6,549,000	5,214,000	3,256,000	266,000
other noncurrent assets and liabilities	-416,000	-738,000	421,000	-382,000	255,000	131,000	156,000	-89,000	360,000	221,000	130,000	158,000	6,000	-1,374,000	-2,288,000	-1,012,000	13,000	7,000	-72,000	350,000
net cash from operating activities	55,510,000	49,808,000	52,164,000	44,515,000	56,694,000	25,732,000	37,659,000	54,182,000	76,012,000	20,961,000	51,517,000	20,894,000	19,246,000	-11,262,000	8,815,000	24,163,000	-7,473,000	532,000	6,537,000	15,329,000	2,197,000	12,140,000	-5,489,000
capex	-5,269,000	-2,843,000	-1,895,000	-1,794,000	-866,000	-850,000	-681,000	-953,000	-759,000	-1,251,000	-721,000	-1,240,000	-490,000	-790,000	-612,000	-718,000	-430,000	-369,000	-97,000	-149,000	-98,000	-693,000	-2,278,000
free cash flows	50,241,000	46,965,000	50,269,000	42,721,000	55,828,000	24,882,000	36,978,000	53,229,000	75,253,000	19,710,000	50,796,000	19,654,000	18,756,000	-12,052,000	8,203,000	23,445,000	-7,903,000	163,000	6,440,000	15,180,000	2,099,000	11,447,000	-7,767,000
investing activities
purchase of property and equipment	-5,269,000	-2,843,000	-1,895,000	-1,794,000	-866,000	-850,000	-681,000	-953,000	-759,000	-1,251,000	-721,000	-1,240,000	-490,000	-790,000	-612,000	-718,000	-430,000	-369,000	-97,000	-149,000	-98,000	-693,000	-2,278,000
purchase of marketable securities	-54,279,000	-145,809,000	0	-11,700,000	-47,833,000	-110,806,000	-166,733,000	-142,362,000	-97,164,000	-23,435,000	-38,178,000	-30,545,000	-34,744,000	-59,867,000	-20,996,000	-7,000,000	-21,335,000	-62,146,000	-38,986,000
sale of marketable securities	29,633,000	63,382,000	76,885,000	28,856,000	140,099,000	131,000,000	74,000,000	79,000,000	39,000,000	40,813,000	37,726,000	29,909,000	33,975,000	21,099,000	15,296,000	30,092,000	52,989,000	23,995,000	50,970,000
acquisition of business, net of cash acquired	0	-9,340,000	0	0
net cash from investing activities	-29,915,000	-94,610,000		15,362,000	86,096,000	19,344,000	-93,414,000	-64,315,000	-58,923,000	16,127,000	-1,173,000	-1,876,000	-1,259,000	-39,558,000	-6,312,000				11,887,000	-9,148,000	-42,077,000	-693,000	-2,278,000
financing activities
repurchase of common stock			-55,102,000	-61,453,000	-159,959,000	-23,764,000																	-3,000
proceeds from exercise of stock options	-21,000	39,000	2,000	109,000	26,000	962,000	1,277,000	449,000	1,449,000	1,675,000	943,000	921,000	379,000	830,000	1,171,000	562,000	652,000	539,000	251,000	649,000
payment of employee taxes related to equity awards	-2,612,000	-3,583,000	-1,612,000	-2,217,000	-3,213,000	-4,959,000	-6,696,000	-3,078,000	-3,611,000	-3,815,000	-4,132,000	-2,322,000	-2,647,000	-2,988,000	-4,860,000	-3,815,000	-5,768,000	-3,523,000	-2,511,000	-2,323,000
proceeds from contributions to employee stock purchase plan	304,000	256,000	385,000	208,000	357,000	350,000	394,000	267,000	323,000	294,000	403,000	173,000	190,000	386,000	375,000	193,000	292,000	487,000	176,000	167,000
net cash from financing activities	-2,329,000	-3,288,000	-56,327,000	-63,353,000	-162,789,000	-27,411,000	-5,025,000	-2,362,000	-1,839,000	-1,846,000	-2,786,000	-1,228,000	-2,078,000	-1,772,000					-2,084,000	-1,608,000	-2,363,000	-194,000	80,485,000
effect of exchange rate changes on cash, cash equivalents, and restricted cash	37,000	15,000
net decrease in cash, cash equivalents, and restricted cash
cash, cash equivalents, and restricted cash, beginning of period	0	162,314,000
cash, cash equivalents, and restricted cash, end of period	23,303,000	114,239,000
cash and cash equivalents	23,267,000	109,239,000
restricted cash included within noncurrent assets	36,000	5,000,000
total cash, cash equivalents, and restricted cash	23,303,000	114,239,000
supplemental disclosure of cash flow information
cash paid for income taxes, net of refunds received	23,942,000	400,000	5,577,000	17,555,000	17,679,000	-362,000	3,863,000	1,620,000	718,000	-20,000	-13,000	86,000	55,000	5,000
supplemental disclosure of non-cash investing and financing activities
additions of property and equipment, net included in accounts payable and accrued expenses	-778,000	1,246,000	105,000	-14,000	3,000	155,000	293,000	-310,000	237,000	201,000	560,000	-227,000	52,000	251,000	-58,000	164,000	78,000	20,000	-9,000
net increase in cash, cash equivalents, and restricted cash		-48,075,000
deferred tax (benefit) expense															-15,447,000	-7,679,000
net cash provided (used in) by investing activities
effect of exchange rate changes on cash and cash equivalents			7,000	-4,000	0	-2,000	1,000	0
net increase in cash and cash equivalents			70,834,000	-3,480,000	-19,999,000	17,663,000	-60,779,000	-12,495,000	15,250,000	35,242,000	47,558,000				-811,000			-40,485,000	16,340,000	4,573,000	-42,242,000	11,252,000	72,718,000
cash and cash equivalents, beginning of year																							0
cash and cash equivalents, end of year																							72,718,000
non-cash interest expense															0	0	19,000	19,000	19,000	19,000	18,000	19,000
cash and cash equivalents, beginning of period				0	0	97,296,000		0	0	120,078,000		0	0	91,413,000		0	0	70,305,000		0	0	80,382,000
cash and cash equivalents, end of period				-3,480,000	-19,999,000	114,959,000		-12,495,000	15,250,000	155,320,000		17,790,000	15,909,000	38,821,000		43,477,000	18,927,000	29,820,000		4,573,000	-42,242,000	91,634,000
realized gains on sale of marketable securities					-3,592,000	-3,395,000				-502,000
foreign currency exchange rate gain
realized gain on sale of marketable securities							-1,627,000	-1,377,000
deferred tax benefit										-1,347,000	127,000	-1,672,000	85,000	-5,155,000
payment of initial public offering costs																			0	-101,000	0	-791,000
net decrease in cash and cash equivalents													15,909,000	-52,592,000

change in fair value of warrant liabilities																							5,757,000
net cash from continuing operations																					2,197,000	12,140,000	-5,489,000
net cash from discontinued operations
proceeds from issuance of common stock upon initial public offering
proceeds from revolving line of credit																							24,175,000
repayments made against revolving line of credit																							-24,175,000
proceeds from exercise of stock warrants
cash paid for interest																							0
deferred initial public offering costs in accounts payable and accrued expenses
non-cash preferred stock warrant conversion to common stock warrant upon ipo
net cash (used in) financing activities																-3,060,000	-4,824,000	-2,497,000
prepaid expenses and current other assets																	445,000	1,046,000	-3,945,000	1,949,000	1,109,000	561,000	-3,666,000
net cash (used in) investing activities																	31,224,000	-38,520,000
net (decrease) in cash and cash equivalents
less: income from discontinued operations, net of income tax
loss on debt extinguishment
accretion of debt discount and debt issuance costs
net cash (used in) continuing operations																			11,887,000	-9,148,000	-42,077,000	-693,000
repayment of term loan
repurchase of convertible preferred stock
exercise of stock warrants
non-cash settlement of liability
non-cash liability forgiveness related to divestiture
purchases of marketable securities
additions of property and equipment, net included in accrued expenses																					21,000	68,000
non-cash deferred initial public offering costs in accounts payable and accrued liabilities																							-1,402,000
exercise of stock options																						597,000	1,529,000
supplemental disclosure of non-cash investing activities
other assets																							287,000
proceeds from issuance of common stock upon initial public offering, net of issuance and offering costs
proceeds from issuance of convertible preferred stock and warrants
payment of deferred initial public offering costs

We provide you with 20 years of cash flow statements for Progyny stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Progyny stock. Explore the full financial landscape of Progyny stock with our expertly curated income statements.

The information provided in this report about Progyny stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.